Attending one of the largest partnering event in Life Science, these days taking place in Stockholm 9-10 September- 2015. This will be an event not only to meet with research partners and Sponsors for Redoxis preclinical models of autoimmunity, but also initiation of discussion with partners for next call to H2020.
Redoxis has been approved by the French authorities “Ministère chargé de l’Enseignement supérieur et de la Recherche” eligible for tax reduction for services performed by Redoxis for French research entities.
For further information please contact us at firstname.lastname@example.org or directly to Peter Olofsson, CEO or Malin Hutqvist, CSO.
This month we started the RISE project REDOXIT for Research and Innovation Staff Exchange (RISE) as a collaborative project with Aston University (Birmingham, UK) and University of Erlangen (Germany). This collaborative project will enable R&D collaboration with exchange of research fellows and methodology between the partners for the coming 4 years.
What is the reason behind neuroinflammation involved in the development of neurodegenerative diseases like Amyotrophic lateral sclerosis, Multiple sclerosis and Epilepsy? Could a family of superoxide-generating enzymes called NOX be a key mediator? How can the answer to the above question be used for developing an efficient cure to these diseases?
A consortium of European researchers in the field of neurology and disease pathology, the EC funded Neurinox consortium coordinated by the University of Geneva, has invested several years of research to find the answer to these questions.
On 23-24 September 2015 at the Molecular Biotechnology Centre in Torino, Italy, the Neurinox consortium organises a symposium where not only its findings will be presented; it will also be the unique opportunity to find out more about the diseases, current treatment options and the latest state-of-the-art research in the understanding of underlying mechanisms and development of efficient treatment options. The symposium addresses all types of stakeholders in the field, including patients, patients associations, the general public, pharmaceutical industry, scientists and biotechnology companies.